The Selective Cytopheretic Device: A Novel Host Response Targeting Cell Directed Extracorporeal Therapy in AKI

Time: 2:00 pm
day: Seminar Day


  • Describing the impact of systemic inflammation as a key driver of organ dysfunction & damage in acute and chronic diseases such as AKI and CKD
  • Targeting leukocytes (neutrophils and monocytes) as the critical effector cells driving systemic inflammation is an attractive alternative to cytokine-targeted therapies
  • Reviewing clinical data of the selective cytopheretic device (SCD) in a variety of populations including pediatric & adult AKI and COVID-19